Traders should monitor for potential downward pressure on the stock; coordinated sales by C-suite executives, especially the CEO and CMO, often signal reduced confidence in near-term prospects. The magnitude is material enough to raise concern but not yet indicative of crisis-level divestment.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $27.17entry
- T+1 · 7mo ago −2.02%α −1.96% · $26.62
- T+5 · 7mo ago +12.48%α +9.29% · $30.56
- T+20 · 6mo ago +10.86%α +3.29% · $30.12
- T+60 · 4mo ago +7.18%α −3.60% · $29.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two top executives at Mineralys Therapeutics, the CEO and Chief Medical Officer, sold shares in a concentrated 7-day window, generating over $1.1 million in proceeds. The sales are open-market transactions, indicating deliberate divestment rather than routine equity management.
Key Financial Metrics
Key Facts
- CEO Jon Congleton sold $422,000 worth of shares in a single open-market transaction on April 13, 2026.
- Chief Medical Officer Rodman David Malcom sold $548,672 in shares across two days (April 13 and 15), following derivative exercises totaling $6,857.
- Total open-market sale value from the cluster: $1.1M over 7 days, representing 0.048% of the company's $2.3B market cap.
- All transactions were coded as S (open-market sale) or M (exercise of derivative), with non-cash derivative exercises also occurring.
Financial Impact
$1.1 million in insider sales over 7 days
Risk Factors
- Perception of insider pessimism ahead of key clinical or regulatory milestones
- Potential for follow-on selling if other insiders exit positions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MLYS-1776303945595 |
Track record
35 reports on MLYS
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 4 of 9 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers